Private Capital Advisors Lowers stake in Thermo Fisher Scientific (TMO)

Thermo Fisher Scientific (TMO) : Private Capital Advisors reduced its stake in Thermo Fisher Scientific by 0.34% during the most recent quarter end. The investment management company now holds a total of 45,780 shares of Thermo Fisher Scientific which is valued at $6,603,765 after selling 155 shares in Thermo Fisher Scientific , the firm said in a disclosure report filed with the SEC on Apr 26, 2016.Thermo Fisher Scientific makes up approximately 2.95% of Private Capital Advisors’s portfolio.

Thermo Fisher Scientific opened for trading at $145.01 and hit $146.7699 on the upside on Monday, eventually ending the session at $146.5, with a gain of 1.56% or 2.25 points. The heightened volatility saw the trading volume jump to 15,37,092 shares. Company has a market cap of $58,052 M.

Other Hedge Funds, Including , Liberty Capital Management reduced its stake in TMO by selling 225 shares or 1.26% in the most recent quarter. The Hedge Fund company now holds 17,588 shares of TMO which is valued at $2,537,069. Thermo Fisher Scientific makes up approx 1.95% of Liberty Capital Management’s portfolio.Peddock Capital Advisors boosted its stake in TMO in the latest quarter, The investment management firm added 28 additional shares and now holds a total of 6,543 shares of Thermo Fisher Scientific which is valued at $960,840. Thermo Fisher Scientific makes up approx 0.70% of Peddock Capital Advisors’s portfolio. Daiwa Sb Investments Ltd. sold out all of its stake in TMO during the most recent quarter. The investment firm sold 1,830 shares of TMO which is valued $265,972.

On the company’s financial health, Thermo Fisher Scientific reported $1.80 EPS for the quarter, beating the analyst consensus estimate by $ 0.06 according to the earnings call on Apr 28, 2016. Analyst had a consensus of $1.74. The company had revenue of $4294.80 million for the quarter, compared to analysts expectations of $4113.28 million. The company’s revenue was up 9.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.63 EPS.

Many Wall Street Analysts have commented on Thermo Fisher Scientific. Company shares were Reiterated by Mizuho on May 3, 2016 to “Buy”, Firm has raised the Price Target to $ 163 from a previous price target of $160 .Thermo Fisher Scientific was Downgraded by Jefferies to ” Hold” on Apr 29, 2016. Company shares were Reiterated by Mizuho on Apr 4, 2016 to “Buy”, Firm has raised the Price Target to $ 160 from a previous price target of $150 .

Thermo Fisher Scientific Inc. is a provider of analytical instruments equipment reagents and consumables software and services for research manufacturing analysis discovery and diagnostics. The company operates through four segments: Life Sciences Solutions provides reagents instruments and consumables used in biological and medical research discovery and production of new drugs and vaccines as well as diagnosis of disease; Analytical Instruments provides instruments consumables software and services that are used in the laboratory; Specialty Diagnostics offers diagnostic test kits reagents culture media instruments and associated products and Laboratory Products and Services offers self-manufactured and sourced products for the laboratory.

Leave a Reply

Thermo Fisher Scientific - Is it time to Sell?

Top Brokerage Firms are advising their investors on Thermo Fisher Scientific. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.